Loading stock data…
RANI
$0.94+0.05 (+5.87%)
Market ClosedLast close May 1
Rani Therapeutics Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rani Therapeutics Holdings, Inc. in the Healthcare sector is trading at $0.94. The stock is currently near its 52-week low of $0.39, remaining 14.5% below its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why RANI maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.94
Potential Upside
5%
Whystock Fair Value$0.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$118.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-89.89%
Volume
Today's trading volume
618,294
Recent News
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Rani Therapeutics Q4 Earnings Call Highlights
Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a “transformational” 2025 during the company’s fourth-quarter and full-year earnings call, pointing to progress advancing its oral biologics delivery platform, the launch of a new clinical study, and a new strategic collab
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 105.13% +2.83, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.48% +0.83, Icici Bank (IBN) 1.10% +0.80, EETH ETF (EETH) 19.93% +0.59, Tradr 2X Long IREN Daily ETF (IREX) 24.34% +0.56, iShares Investment Grade Corporate Bond ETF (LQD) 3.00% +0.55, Beyond Meat (BYND) 12.97% +0.49, Rani Therapeutics Holdings (RANI) 18.04% +0.44, Direxion Daily 20 plus Year Treasury Bear
Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%
Key Insights Rani Therapeutics Holdings' significant retail investors ownership suggests that the key decisions are...
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent […]